Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan.
Sci Signal. 2010 Nov 16;3(148):ra83. doi: 10.1126/scisignal.2000954.
Tumor necrosis factor (TNF) is an inflammatory cytokine that has important roles in various immune responses, which are mediated through its two receptors, TNF receptor 1 (TNFR1) and TNFR2. Antibody-based therapy against TNF is used clinically to treat several chronic autoimmune diseases; however, such treatment sometimes results in serious side effects, which are thought to be caused by the blocking of signals from both TNFRs. Therefore, knowledge of the structural basis for the recognition of TNF by each receptor would be invaluable in designing TNFR-selective drugs. Here, we solved the 3.0 angstrom resolution structure of the TNF-TNFR2 complex, which provided insight into the molecular recognition of TNF by TNFR2. Comparison to the known TNFR1 structure highlighted several differences between the ligand-binding interfaces of the two receptors. Additionally, we also demonstrated that TNF-TNFR2 formed aggregates on the surface of cells, which may be required for signal initiation. These results may contribute to the design of therapeutics for autoimmune diseases.
肿瘤坏死因子(TNF)是一种炎症细胞因子,在各种免疫反应中具有重要作用,这些反应是通过其两个受体,TNF 受体 1(TNFR1)和 TNFR2 介导的。针对 TNF 的抗体疗法在临床上被用于治疗几种慢性自身免疫性疾病;然而,这种治疗有时会导致严重的副作用,这些副作用被认为是由于阻断了两个 TNFR 的信号。因此,了解每个受体识别 TNF 的结构基础对于设计 TNFR 选择性药物将是非常宝贵的。在这里,我们解决了 3.0 埃分辨率的 TNF-TNFR2 复合物结构,这为理解 TNFR2 对 TNF 的分子识别提供了线索。与已知的 TNFR1 结构的比较突出了两个受体配体结合界面之间的几个差异。此外,我们还证明了 TNF-TNFR2 在细胞表面形成聚集体,这可能是信号起始所必需的。这些结果可能有助于设计用于自身免疫性疾病的治疗方法。